Though the 2021 HLTH conference ended last week, our reporters are still bringing you news and interviews from those days in Boston.
This week, reporters Mohana Ravindranath and Shelby Livingston wrote about a new partnership between Highmark Health, an $18 billion healthcare system, and Verily. The two giant companies are partnering in an effort to increase value-based care.
Meanwhile reporter Andrew Dunn wrote about his interviews with biotech entrepreneur Alexis Borisy, and why EQRx is Borisy's biggest venture yet.
Andrew also spoke to chief Regeneron scientist George Yancopoulos, who had some advice for all the CRISPR-based gene editing companies out there.
Also at HLTH, reporter Megan Hernbroth spoke to institutional healthcare investors who said they were worried about the sudden increase of cash in the space from tech investors like Tiger Global Management.
They say that these massive influxes of cash are partially responsible for pushing company valuations to astronomically high levels.
Our reporters noted other new investment news this week. Mohana wrote about why investors seem to be interested in Cityblock, even though it's a startup in the traditionally underfunded Medicaid sector.
In more encouraging COVID-19 news, a large study just found that a cheap and common antidepressant called fluvoxamine lowers the risk of hospitalization from COVID-19 in high-risk patients, Erin Snodgrass wrote.
No comments